Investigation and Analysis on the Causes Affecting the Production of One Pig Farm in Southwest Region

To analyze the causes affecting production situation of one pig farm in southwest region,group leader,assistant and related staffs in the pig farm were queried,mating and delivery situation of sow and dead-culling situation ofpigletwere investigated.The results showed that(1) mating situation: mating 691 pigs,returning to love 42 pigs,abortion 4 pigs,mismatching rate was 7.59%.(2) Delivery situation: delivering 175 nests,total birth 2538,total piglet per fetus 14.5,average healthy piglet per fetus 10.12,invalid piglet rate was30.21%.Among them,mummy fetus,dead fetus,weak piglet and deformity accounted for 47.78%,35.64%,10.71% and 5.87% of invalid piglet.(3) Dead-culling situation: dead-culling rate in breeding process was 12.37%.Among them,diarrhea death wasthemain cause,accounting for 44.47%,followed by pressing,falling to the ground,disease,joint swelling,weakness and other causes,and they respectively accounted for 18.58%,13.36%,13.36%,8.56%,5.85% and 0.62%.

The earlier,the better?A review of neoadjuvant immunotherapy in resectable non-small-cell lung cancer

Immune checkpoint inhibitors(ICIs)have revolutionized the approach to advanced and locally advanced non-small-cell lung cancer(NSCLC).Antibodies blocking inhibitory immune checkpoints,such as programmed death 1(PD-1)and its ligand(PD-L1),have remarkable antitumor efficacy and have been approved as a standard first-or second-line treatment in non-oncogene-addicted advanced NSCLC.The successful application of immunotherapy in advanced lung cancer has motivated researchers to further evaluate its clinical role as a neoadjuvant setting for resectable NSCLC and for improved long-term overall survival and curative rates.In this review,we discuss the efforts that incorporate ICIs into the treatment paradigm for surgically resectable lung cancer.We reviewed the early-phase results from neoadjuvant clinical trials,the landscape of the majority of ongoing phase III trials,and discuss the prospects of ICIs as a curative therapy for resectable lung cancer.We also summarized the potential biomarkers and beneficiaries involved in the current study,as well as the remaining unresolved challenges for neoadjuvant immunotherapy.

Non-Ischemic, Non-Hypoxic Myocardial Injury, and Long-Term Mortality in Patients with Coronavirus Disease 2019: A Retrospective Cohort Study

Objective:Cardiac damage is commonly reported in patients with coronavirus disease 2019(COVID-19)but its prevalence and impact on the long-term survival of patients remain uncertain.This study aimed to explore the prevalence of myocardial injury and assess its prognostic value in patients with COVID-19.Methods:A single-center,retrospective cohort study was performed at the Affiliated Hospital of Jianghan University.Data from 766 patients with confirmed COVID-19 who were hospitalized from December 27,2019 to April 25,2020 were collected.Demographic,clinical,laboratory,electrocardiogram,treatment data and all-cause mortality during follow-up were collected and analyzed.Results:Of the 766 patients with moderate to critically ill COVID-19,86(11.2%)died after a mean follow-up of 72.8 days.Myocardial injury occurred in 94(12.3%)patients.The mortality rate was 64.9%(61/94)and 3.7%(25/672)in patients with and without myocardial injury,respectively.Cox regression showed that myocardial injury was an independent risk factor for mortality(hazard ratio:8.76,95%confidence interval:4.76–16.11,P<0.001).Of the 90 patients with myocardial injury with electrocardiogram results,sinus tachycardia was present in 29,bundle branch block in 26,low voltage in 10,and abnormal T-wave in 53.Conclusions:COVID-19 not only involves pneumonia but also cardiac damage.Myocardial injury is a common complication and an independent risk factor for mortality in COVID-19 patients.

Atrial of arbidol hydrochloride in adults with COVID-19

Background: To date, there is no effective medicine to treat coronavirus disease 2019 (COVID-19), and the antiviral efficacy of arbidol in the treatment for COVID-19 remained equivocal and controversial. The purpose of this study was to evaluate the efficacy and safety of arbidol tablets in the treatment of COVID-19.Methods: This was a prospective, open-label, controlled and multicenter investigator-initiated trial involving adult patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Patients were stratified 1:2 to either standard-of-care (SOC) or SOC plus arbidol tablets (oral administration of 200 mg per time, three times a day for 14 days). The primary endpoint was negative conversion of SARS-CoV-2 within the first week. The rates and 95% confidential intervals were calculated for each variable.Results: A total of 99 patients with laboratory-confirmed SARS-CoV-2 infection were enrolled;66 were assigned to the SOC plus arbidol tablets group, and 33 to the SOC group. The negative conversion rate of SARS-CoV-2 within the first week in patients receiving arbidol tablets was significantly higher than that of the SOC group (70.3% [45/64]vs. 42.4% [14/33];difference of conversion rate 27.9%;95% confidence interval [CI], 7.7%-48.1%;P=0.008). Compared to those in the SOC group, patients receiving arbidol tablets had a shorter duration of clinical recovery (median 7.0 daysvs. 12.0 days;hazard ratio [HR]: 1.877, 95% CI: 1.151-3.060,P=0.006), symptom of fever (median 3.0 daysvs. 12.0 days;HR: 18.990, 95% CI: 5.350-67.410,P<0.001), as well as hospitalization (median 12.5 daysvs. 20.0 days;P<0.001). Moreover, the addition of arbidol tablets to SOC led to more rapid normalization of declined blood lymphocytes (median 10.0 daysvs. 14.5 days;P > 0.05). The most common adverse event in the arbidol tablets group was the elevation of transaminase (5/200, 2.5%), and no one withdrew from the study due to adverse events or disease progression.Conclusions: SOC plus arbidol tablets significantly increase the negative conversion rate of SARS-CoV-2 within the first week and accelerate the recovery of COVID-19 patients. During the treatment with arbidol tablets, we find no significant serious adverse events.